Outcome and risk factor of immune‐related adverse events and pneumonitis in patients with advanced or postoperative recurrent non‐small cell lung cancer treated with immune checkpoint inhibitors

BACKGROUND: Non‐small cell lung cancer (NSCLC) patients with pre‐existing respiratory diseases have been excluded in clinical trials of immune checkpoint inhibitor (ICI) therapy, and it is unknown whether the same degree of response can be expected as that in patients without pre‐existing respirator...

Descripción completa

Detalles Bibliográficos
Autores principales: Isono, Taisuke, Kagiyama, Naho, Takano, Kenji, Hosoda, Chiaki, Nishida, Takashi, Kawate, Eriko, Kobayashi, Yoichi, Ishiguro, Takashi, Takaku, Youtaro, Kurashima, Kazuyoshi, Yanagisawa, Tsutomu, Takayanagi, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812074/
https://www.ncbi.nlm.nih.gov/pubmed/33201587
http://dx.doi.org/10.1111/1759-7714.13736

Ejemplares similares

Ejemplares similares